MENU
+Compare
SPRY
Stock ticker: NASDAQ
AS OF
Sep 26 closing price
Price
$9.80
Change
+$0.26 (+2.73%)
Capitalization
968.5M

SPRY ARS Pharmaceuticals Forecast, Technical & Fundamental Analysis

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis... Show more

SPRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for SPRY with price predictions
Sep 26, 2025

SPRY's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SPRY turned positive on September 18, 2025. Looking at past instances where SPRY's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SPRY's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SPRY entered a downward trend on September 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.035) is normal, around the industry mean (19.823). P/E Ratio (152.500) is within average values for comparable stocks, (53.778). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.098). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (9.001) is also within normal values, averaging (349.540).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SPRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

SPRY is expected to report earnings to -46 cents per share on November 06

ARS Pharmaceuticals SPRY Stock Earnings Reports
Q3'25
Est.
$-0.46
Q2'25
Est.
$-0.46
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.61
Q3'24
Missed
by $0.06
The last earnings report on August 13 showed earnings per share of -46 cents, meeting the estimate of -46 cents. With 2.51M shares outstanding, the current market capitalization sits at 968.50M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11682 El Camino Real
Phone
+1 858 771-9307
Employees
26
Web
https://www.ars-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BWLRX26.180.28
+1.08%
American Beacon Man Lg Cp Value R6
QUERX21.980.18
+0.83%
AQR Large Cap Defensive Style R6
PSEPX19.960.13
+0.66%
1789 Growth and Income P
BAWAX54.700.29
+0.53%
Brown Advisory Sustainable Growth Adv
PGIAX38.630.19
+0.49%
Putnam Focused Equity A

SPRY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with ANAB. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then ANAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRY
1D Price
Change %
SPRY100%
+2.73%
ANAB - SPRY
36%
Loosely correlated
+6.99%
KROS - SPRY
33%
Loosely correlated
+1.58%
REPL - SPRY
31%
Poorly correlated
+1.98%
NUVL - SPRY
30%
Poorly correlated
+4.99%
SMMT - SPRY
29%
Poorly correlated
+3.41%
More